Akebia Therapeutics, Inc. (AKBA) vs BioAge Labs Inc. (BIOA)
A side-by-side comparison of Akebia Therapeutics, Inc. and BioAge Labs Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
AKBA
Akebia Therapeutics, Inc.
$0.90HealthcareDelayed quote: Oct 6, 2026, 9:30 AM EDT
BIOA
BioAge Labs Inc.
$6.44HealthcareDelayed quote: Oct 6, 2026, 9:30 AM EDT
Total return — AKBA vs BIOA
growth of $100 · dividends reinvested · last 2yAKBA -31.5% (-17.3%/yr)BIOA -65.3% (-41.1%/yr)AKBA compounded faster over this window
AKBA BIOA
AKBA vs BIOA: by the numbers
- •BIOA is the larger company ($242M vs $242M market cap).
- •Both run net losses; AKBA's is the smaller (-13.54% vs -912.25% net margin).
Metrics side by side
Valuation
| Metric | AKBA | BIOA |
|---|---|---|
| P/S ratio | 1.10 | 23.42 |
| P/B ratio | 9.66 | 0.65 |
| FCF yield | 16.62% | N/A |
Profitability
| Metric | AKBA | BIOA |
|---|---|---|
| Gross margin | 79.48% | 99.39% |
| Operating margin | 9.95% | -1026.28% |
| Net margin | -13.54% | -912.25% |
| ROE | -118.58% | -25.20% |
| ROIC | -7.08% | -28.14% |
Growth (annualized)
| Metric | AKBA | BIOA |
|---|---|---|
| Revenue CAGR (5Y) | -0.26% | N/A |
| Total return CAGR (5Y) | -20.07% | N/A |
Go deeper
Dig into the metrics
Akebia Therapeutics ROEBioAge Labs ROEAkebia Therapeutics operating marginBioAge Labs operating marginAkebia Therapeutics revenue growthBioAge Labs revenue growthAkebia Therapeutics free cash flowBioAge Labs free cash flow
Akebia Therapeutics & BioAge Labs appear in these rankings
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.